small nuclear ribonucleoprotein polypeptide G pseudogene 15Genealiases: []
Q-omics provides the consensus-scored SNRPGP15 profile across patient tissues and cancer cell-line models. SNRPGP15 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNRPGP15 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, SNRPGP15 RNA expression shows 18,934 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, LIHC, and UVM as cancer lineages where SNRPGP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPGP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPGP15 survival associations across molecular data types. SNRPGP15 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPGP15 RNA expression–survival associations across cancer types. High SNRPGP15 expression shows unfavorable associations in ACC, KICH, UVM, UCEC and THCA, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNRPGP15 RNA expression.
This table summarizes SNRPGP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPGP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPGP15 shows lower tumor expression in KICH and higher tumor expression in LIHC, BRCA, CHOL, PAAD and ESCA. The LIHC box plot shows higher SNRPGP15 RNA expression in tumor versus normal tissue (log2 FC = +0.432, t-test p < 0.001).
This table shows molecular features associated with SNRPGP15 in patient tissues and cancer cell lines. In patient samples, SNRPGP15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
